To hear about similar clinical trials, please enter your email below
Trial Title:
Esophagogastric Histopathology Potentially Guided Patients Younger Than 50 Years Old to Undergo Colonoscopy Earlier
NCT ID:
NCT05832372
Condition:
Colorectal Neoplasms
Conditions: Official terms:
Colorectal Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Summary:
Colorectal cancer (CRC) is the third most diagnosed cancer worldwide and second leading
cause of cancer death. Most CRCs arise from a polyp, developing through two major
precursor lesion pathways: the traditional adenoma-carcinoma pathway, and the serrated
neoplasia pathway. This provides opportunities to prevent cancer by removing its
precursor lesions. CRC screening efforts are directed toward removal of precancerous
polyps with colonoscopy and detection of early-stage CRC, which has been demonstrated to
reduce CRC incidence and mortality effectively, making CRC one of the most preventable
and treatable forms of cancer.
Current guidelines in China recommend starting CRC screening uniformly at age 50 in
average-risk individuals. However, a one-fits-all approach to determining CRC screening
starting age may be not conducive to personalized screening, especially in the developing
countries with scarce health resources. The incidence of early-onset CRC (CRC diagnosed
before the age of 50) has shown a continuous increasing trend worldwide, spurring the US
Preventive Services Task Force to recommend initiating average-risk CRC screening at age
45 instead of 50. Furthermore, different populations may benefit from even earlier
screening, and CRC incidence may differ on the basis of population characteristics and
CRC risk factors. For individuals younger than 50 years old, earlier screening based on
risk factors may address this concern.
Previous studies have recommended earlier starting age of CRC screening combined with
risk factors such as but not limited to sex, age, family history, lifestyle and
comorbidity. Some upper gastrointestinal diseases have also been reported to be
associated with an increased risk of colorectal neoplasms, which may be related to the
destruction of gastric acid barrier function and long-term use of pump proton inhibitors.
Compared with colonoscopy examination, individuals were more willing to undergo
esophagogastroduodenoscopy (EGD) examination for gastric cancer screening, especially
among the younger, potentially utilizing the EGD to guide earlier colonoscopies for
patients at increased risk. Therefore, this study was aimed to investigate the
association between esophagogastric histopathology and colorectal neoplasms in patients
under the age of 50 and whether these risks factor could be combined with to guide
earlier CRC screening.
Criteria for eligibility:
Study pop:
This retrospective observational study analyzed records between November 7, 2020, and
November 14, 2022 which were extracted from Qilu Hospital of Shandong University.
Patients younger than 50 years old who underwent gastroscopy and colonoscopy
simultaneously, were selected and enrolled.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
Patients younger than 50 years old who underwent gastroscopy and colonoscopy
simultaneously.
Exclusion Criteria:
1. Patients without a good bowel preparation (Boston Bowel Preparation Scale [BBPS]
score ≥ 6);
2. Incomplete gastroscopy or colonoscopy examinations;
3. Partial or total gastrointestinal resection;
4. Patients who have been diagnosed with gastrointestinal cancer before endoscopy;
5. Hereditary polyposis, including Peutz-Jeghers syndrome, and familial adenomatous
polyposis;
6. A history of inflammatory bowel diseases.
Gender:
All
Minimum age:
18 Years
Maximum age:
50 Years
Healthy volunteers:
No
Start date:
May 1, 2023
Completion date:
May 27, 2023
Lead sponsor:
Agency:
Shandong University
Agency class:
Other
Source:
Shandong University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05832372
